EKF Diagnostics Holdings plc (FRA:LYF)

Market Cap	124.24M -11.4%
Revenue (ttm)	59.11M +2.7%
Net Income	2.43M -66.0%
EPS	0.01 -65.8%
Shares Out	n/a
PE Ratio	51.07
Forward PE	15.41
Dividend	n/a
Ex-Dividend Date	n/a

Volume	752
Open	0.2720
Previous Close	0.2800
Day's Range	0.2720 - 0.2720
52-Week Range	0.2520 - 0.3400
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 15, 2026

About EKF Diagnostics Holdings

EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally. The company offers DiaSpect Tm analyzer; Hemo Control, a hemoglobin analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. It also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab HbA1c, a desktop point...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 1990
• Employees: 301
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: LYF

Financial Performance

In 2025, EKF Diagnostics Holdings's revenue was 51.56 million, an increase of 2.73% compared to the previous year's 50.19 million. Earnings were 2.12 million, a decrease of -66.00%.

Financial numbers in GBP

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error